FrancophonIA/ELRC3.0 huggingface dataset:
English: Exforge HCT tablets contain three substances called amlodipine, valsartan and hydrochlorothiazide.
Slovenian: Tablete Exforge HCT vsebujejo tri učinkovine: amlodipin, valsartan in hidroklorotiazid.
English: If Exforge HCT is used during breast-feeding, doses should be kept as low as possible.
Slovenian: Če bolnica uporablja zdravilo Exforge HCT v času dojenja, naj uporablja čim nižje odmerke.
English: Due to the hydrochlorothiazide component, Exforge HCT is contraindicated in symptomatic hyperuricaemia.
Slovenian: Zaradi vsebnosti hidroklorotiazida je pri bolnikih s simptomatsko hiperurikemijo uporaba zdravila Exforge HCT kontraindicirana.
English: There are no clinical studies on fertility with Exforge HCT.
Slovenian: Kliničnih študij glede plodnosti pri uporabi zdravila Exforge HCT ni.
English: The maximum recommended dose of Exforge HCT is 10 mg/320 mg/25 mg.
Slovenian: Najvišji priporočeni odmerek zdravila Exforge HCT je 10 mg/320 mg/25 mg.
English: If you forget to take Exforge HCT
Slovenian: Če ste pozabili vzeti zdravilo Exforge HCT
English: The reductions in systolic/diastolic blood pressure with Exforge HCT were 7.6/5.0 mmHg greater than with valsartan/hydrochlorothiazide, 6.2/3.3 mmHg greater than with amlodipine/valsartan, and 8.2/5.3 mmHg greater than with amlodipine/hydrochlorothiazide.
Slovenian: Znižanje sistoličnega/diastoličnega krvnega tlaka je bilo z zdravilom Exforge HCT za 7,6/5,0 mmHg večje kot s kombinacijo valsartan/hidroklorotiazid, za 6,2/3,3 mmHg večje kot s kombinacijo amlodipin/valsartan in za 8,2/5,3 mmHg večje kot s kombinacijo amlodipin/hidroklorotiazid.
English: When Exforge HCT is used in patients with renal impairment periodic monitoring of serum electrolytes (including potassium), creatinine and uric acid serum levels is recommended.
Slovenian: Pri bolnikih z okvaro ledvic, ki jemljejo zdravilo Exforge HCT, je priporočljivo periodično kontrolirati koncentracije elektrolitov v serumu (vključno s koncentracijami kalija), kreatinina in sečne kisline.
English: Concomitant use of Exforge HCT with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
Slovenian: Sočasna uporaba zdravila Exforge HCT in zdravil, ki vsebujejo aliskiren, je kontraindicirana pri bolnikih s sladkorno boleznijo ali z okvaro ledvic (GFR <60 ml/min/1,73m2) (glejte poglavji 4.5 in 5.1).
English: Exforge HCT is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is a newborn, or was born prematurely.
Slovenian: Če želite dojiti, bo zdravnik za vas izbral drugo zdravilo, še posebno če je vaš otrok še novorojenček ali je bil rojen prezgodaj.
English: Exforge HCT should be used with caution to treat hypertension in patients with unilateral or bilateral renal artery stenosis or stenosis to a solitary kidney since blood urea and serum creatinine may increase in such patients.
Slovenian: Pri bolnikih z enostransko ali obojestransko stenozo ledvične arterije oz. s stenozo v primeru solitarne ledvice je pri zdravljenju hipertenzije z zdravilom Exforge HCT potrebna previdnost, saj pri takih bolnikih lahko pride do zvišanja koncentracij sečnine v krvi in kreatinina v serumu.
English: The following adverse reactions, listed by MedDRA System Organ Class and frequency, concern Exforge HCT (amlodipine/valsartan/HCT) and amlodipine, valsartan and HCT individually.
Slovenian: Spodaj navedeni neželeni učinki, ki so našteti po MedDRA razvrstitvi organskih sistemov in po pogostnosti, se nanašajo na zdravilo Exforge HCT (amlodipin/valsartan/hidroklorotiazid) in na amlodipin, valsartan in hidroklorotiazid posamezno.
English: Before switching to Exforge HCT patients should be controlled on stable doses of the monocomponents taken at the same time.
Slovenian: Preden bolnik preide na uporabo zdravila Exforge HCT, mora biti njegov krvni tlak urejen s sočasno uporabo stabilnih odmerkov posameznih učinkovin.
English: Due to the valsartan component, Exforge HCT is contraindicated in patients with severe hepatic impairment (see section 4.3).
Slovenian: Zaradi vsebnosti valsartana je zdravilo Exforge HCT kontraindicirano pri bolnikih s hudo okvaro jeter (glejte poglavje 4.3).
English: Do not use any Exforge HCT pack that is damaged or shows signs of tampering.
Slovenian: Zdravila Exforge HCT ne uporabljajte, če je ovojnina poškodovana ali opazite, da je bila že odprta.
English: Due to the valsartan component, Exforge HCT is contraindicated in patients with hepatic impairment (see sections 4.2 and 4.3).
Slovenian: Zaradi vsebnosti valsartana je zdravilo Exforge HCT kontraindicirano pri bolnikih z okvaro jeter (glejte poglavji 4.2 in 4.3).
English: At week 8, the mean reductions in systolic/diastolic blood pressure were 39.7/24.7 mmHg with Exforge HCT, 32.0/19.7 mmHg with valsartan/hydrochlorothiazide, 33.5/21.5 mmHg with amlodipine/valsartan, and 31.5/19.5 mmHg with amlodipine/hydrochlorothiazide.
Slovenian: Po 8 tednih je bilo povprečno znižanje sistoličnega/diastoličnega krvnega tlaka 39,7/24,7 mmHg z zdravilom Exforge HCT, 32,0/19,7 mmHg s kombinacijo valsartan/hidroklorotiazid, 33,5/21,5 mmHg s kombinacijo amlodipin/valsartan in 31,5/19,5 mmHg s kombinacijo amlodipin/ hidroklorotiazid.
English: Amlodipine/Valsartan/Hydrochlorothiazide
Slovenian: Amlodipin/valsartan/hidroklorotiazid
English: In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan, and therefore, Exforge HCT is not suitable in this group of patients (see sections 4.2, 4.3 and 5.2).
Slovenian: Pri bolnikih z blago do zmerno okvaro jeter brez holestaze je najvišji priporočeni odmerek valsartana 80 mg, zato zdravilo Exforge HCT ni primerno za to skupino bolnikov (glejte poglavja 4.2, 4.3 in 5.2).
English: There is no experience on the use of Exforge HCT in pregnant women.
Slovenian: Z uporabo zdravila Exforge HCT pri nosečnicah ni nobenih izkušenj.
English: In patients with mild to moderate hepatic impairment without cholestasis, the maximum recommended dose is 80 mg valsartan and therefore Exforge HCT is not suitable in this group of patients (see sections 4.3, 4.4 and 5.2).
Slovenian: Pri bolnikih z blago do zmerno okvaro jeter brez holestaze je najvišji priporočeni odmerek valsartana 80 mg, zato zdravilo Exforge HCT ni primerno za to skupino bolnikov (glejte poglavja 4.3, 4.4 in 5.2).
English: Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 5 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/320 mg/25 mg film-coated tablets
Slovenian: Exforge HCT 5 mg/160 mg/12,5 mg filmsko obložene tablete Exforge HCT 10 mg/160 mg/12,5 mg filmsko obložene tablete Exforge HCT 5 mg/160 mg/25 mg filmsko obložene tablete Exforge HCT 10 mg/160 mg/25 mg filmsko obložene tablete Exforge HCT 10 mg/320 mg/25 mg filmsko obložene tablete
English: If any of the above applies to you, do not take Exforge HCT and talk to your doctor.
Slovenian: Če kaj od naštetega velja za vas, ne vzemite zdravila Exforge HCT, temveč povejte zdravniku.
English: Treatment with Exforge HCT should only start after correction of hypokalaemia and any coexisting hypomagnesaemia.
Slovenian: Zdravljenje z zdravilom Exforge HCT je mogoče uvesti šele po korekciji hipokaliemije in morebitne sočasne hipomagneziemije.
English: Excessive hypotension, including orthostatic hypotension, was seen in 1.7% of patients treated with the maximum dose of Exforge HCT (10 mg/320 mg/25 mg) compared to 1.8% of valsartan/hydrochlorothiazide (320 mg/25 mg) patients, 0.4% of amlodipine/valsartan (10 mg/320 mg) patients, and 0.2% of hydrochlorothiazide/amlodipine (25 mg/10 mg) patients in a controlled trial in patients with moderate to severe uncomplicated hypertension.
Slovenian: V kontroliranem preskušanju pri bolnikih z zmerno do hudo nezapleteno hipertenzijo so čezmerno hipotenzijo, vključno z ortostatsko hipotenzijo, opažali pri 1,7 % bolnikov, ki so prejemali najvišji odmerek zdravila Exforge HCT (10 mg/320 mg/25 mg), v primerjavi z 1,8 % bolnikov, ki so prejemali valsartan/hidroklorotiazid (320 mg/25 mg), z 0,4 % bolnikov, ki so prejemali amlodipin/valsartan (10 mg/320 mg), in z 0,2 % bolnikov, ki so prejemali hidroklorotiazid/amlodipin (25 mg/10 mg).
English: Stopping your treatment with Exforge HCT may cause your disease to get worse.
Slovenian: Če ste prenehali jemati zdravilo Exforge HCT Če prenehate jemati zdravilo Exforge HCT, se lahko vaša bolezen poslabša.
English: Caution, including more frequent monitoring of blood pressure, is recommended in elderly patients, particularly at the maximum dose of Exforge HCT, 10 mg/320 mg/25 mg, since available data in this patient population are limited.
Slovenian: Pri starejših bolnikih je priporočena previdnost, kar vključuje bolj pogosto merjenje krvnega tlaka, zlasti pri uporabi najvišjega odmerka zdravila Exforge HCT 10 mg/320 mg/25 mg, saj je za to skupino bolnikov na voljo le malo podatkov.
English: Exforge HCT should be used only after correction of any pre-existing sodium and/or volume depletion.
Slovenian: Zdravilo Exforge HCT se sme uporabiti šele po ureditvi morebitnega že prisotnega primanjkljaja natrija in/ali hipovolemije.
English: Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Exforge HCT, 10 mg/320 mg/25 mg, since available data in these patient populations is limited.
Slovenian: Pri bolnikih s srčnim popuščanjem in koronarno boleznijo je priporočena previdnost, zlasti pri uporabi najvišjega odmerka zdravila Exforge HCT 10 mg/320 mg/25 mg, saj je pri teh skupinah bolnikov na voljo le malo podatkov.
English: Caution is advised in patients with heart failure and coronary artery disease, particularly at the maximum dose of Exforge HCT, 10 mg/320 mg/25 mg.
Slovenian: Pri bolnikih s srčnim popuščanjem in koronarno boleznijo je priporočena previdnost, zlasti pri uporabi najvišjega odmerka zdravila Exforge HCT 10 mg/320 mg/25 mg.
English: There is no experience of overdose with Exforge HCT.
Slovenian: Izkušenj s prevelikim odmerjanjem zdravila Exforge HCT ni.
English: Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 5 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiazide
Slovenian: Exforge HCT 5 mg/160 mg/12,5 mg filmsko obložene tablete Exforge HCT 10 mg/160 mg/12,5 mg filmsko obložene tablete Exforge HCT 5 mg/160 mg/25 mg filmsko obložene tablete Exforge HCT 10 mg/160 mg/25 mg filmsko obložene tablete Exforge HCT 10 mg/320 mg/25 mg filmsko obložene tablete amlodipin/valsartan/hidroklorotiazid
English: Protect your skin from sun exposure and UV rays while taking Exforge HCT.
Slovenian: Med jemanjem zdravila Exforge HCT zaščitite kožo pred izpostavljenostjo soncu in UV-žarkom.
English: How to take Exforge HCT
Slovenian: Kako jemati zdravilo Exforge HCT
English: Exforge HCT 10 mg/320 mg/25 mg film-coated tablets
Slovenian: Exforge HCT 10 mg/320 mg/25 mg filmsko obložene tablete
English: You should never take Exforge HCT again.
Slovenian: Ti bolniki ne smejo več prejemati zdravila Exforge HCT.
English: Grapefruit and grapefruit juice should not be consumed by people who are prescribed Exforge HCT.
Slovenian: Zdravilo Exforge HCT skupaj s hrano, pijačo in alkoholom Ljudje, ki jim je zdravnik predpisal zdravilo Exforge HCT, ne smejo uživati grenivk in grenivkinega soka.
English: There is limited experience with the use of Exforge HCT, particulary at the maximum dose, in patients with heart failure and coronary artery disease.
Slovenian: Pri bolnikih s srčnim popuščanjem in koronarno boleznijo je le malo izkušenj z uporabo zdravila Exforge HCT, zlasti z uporabo najvišjega odmerka.
English: Exforge HCT should be discontinued immediately in patients who develop angioedema and should not be re-administered.
Slovenian: Bolnikom, pri katerih pride do angioedema, je treba zdravilo Exforge HCT takoj ukiniti.
English: if you had an allergic reaction to other high blood pressure medicines or diuretics (a type of medicine also known as “water tablets”), especially if you suffer from asthma and allergies if you have been sick (vomiting or diarrhoea).
Slovenian: Če imate to bolezen, uporaba zdravila Exforge HCT za vas ni priporočena; če imate bolezen, ki se imenuje sistemski eritematozni lupus (ki ga kratko imenujemo tudi “lupus” ali s kratico “SLE”); če imate sladkorno bolezen (visoko raven sladkorja v krvi); če imate visoke ravni holesterola ali trigliceridov v krvi; če imate po izpostavljanju soncu kožne reakcije, npr izpuščaj; če ste že imeli alergijsko reakcijo na druga zdravila za uravnavanje visokega krvnega tlaka ali na diuretike (skupino zdravil, ki jim pravimo tudi “tablete za odvajanje vode”), zlasti če imate astmo ali alergije;
English: EU/1/09/569/007 280 film-coated tablets
Slovenian: EU/1/09/569/007 280 filmsko obloženih tablet
English: What Exforge HCT contains
Slovenian: Kaj vsebuje zdravilo Exforge HCT
English: EU/1/09/569/004 56 film-coated tablets
Slovenian: EU/1/09/569/004 56 filmsko obloženih tablet
English: EU/1/09/569/043 280 film-coated tablets
Slovenian: EU/1/09/569/043 280 filmsko obloženih tablet
English: EU/1/09/569/016 56 film-coated tablets
Slovenian: EU/1/09/569/016 56 filmsko obloženih tablet
English: EU/1/09/569/042 98 film-coated tablets
Slovenian: EU/1/09/569/042 98 filmsko obloženih tablet
English: EU/1/09/569/018 98 film-coated tablets
Slovenian: EU/1/09/569/018 98 filmsko obloženih tablet
English: Exforge HCT 10 mg/160 mg/25 mg film-coated tablets
Slovenian: Exforge HCT 10 mg/160 mg/25 mg filmsko obložene tablete
English: Exforge HCT 5 mg/160 mg/25 mg film-coated tablets
Slovenian: Exforge HCT 5 mg/160 mg/25 mg filmsko obložene tablete
English: Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets
Slovenian: Exforge HCT 5 mg/160 mg/12,5 mg filmsko obložene tablete
English: Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets
Slovenian: Exforge HCT 10 mg/160 mg/12,5 mg filmsko obložene tablete
English: EU/1/09/569/027 30 film-coated tablets
Slovenian: EU/1/09/569/027 30 filmsko obloženih tablet
English: Exforge HCT 10 mg/320 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VFL” on the other side.
Slovenian: Exforge HCT 10 mg/320 mg/25 mg filmsko obložene tablete so rjavo rumene ovalne tablete z oznako “NVR” na eni strani in “VFL” na drugi.
English: EU/1/09/569/031 280 film-coated tablets
Slovenian: EU/1/09/569/031 280 filmsko obloženih tablet
English: Exforge HCT is contraindicated in patients with severe renal impairment, anuria or undergoing dialysis (see section 4.3).
Slovenian: Pri bolnikih s hudo okvaro ledvic, z anurijo in pri bolnikih na dializi je uporaba zdravila Exforge HCT kontraindicirana (glejte poglavje 4.3).
English: Exforge HCT individual component
Slovenian: Sočasna uporaba ni priporočena posamezna sestavina zdravila Exforge HCT
English: EU/1/09/569/041 90 film-coated tablets
Slovenian: EU/1/09/569/041 90 filmsko obloženih tablet
English: No dose adjustment of Exforge HCT is required for patients with mild to moderate renal impairment (GFR ≥30 ml/min/1.73 m
Slovenian: Pri bolnikih z blago do zmerno okvaro ledvic (GFR ≥30 ml/min/1,73 m 2) odmerka zdravila Exforge
English: EU/1/09/569/006 98 film-coated tablets
Slovenian: EU/1/09/569/006 98 filmsko obloženih tablet
English: EU/1/09/569/038 28 film-coated tablets
Slovenian: EU/1/09/569/038 28 filmsko obloženih tablet
English: EU/1/09/569/001 14 film-coated tablets
Slovenian: EU/1/09/569/001 14 filmsko obloženih tablet
English: EU/1/09/569/055 280 film-coated tablets
Slovenian: EU/1/09/569/055 280 filmsko obloženih tablet
English: EU/1/09/569/030 98 film-coated tablets
Slovenian: EU/1/09/569/030 98 filmsko obloženih tablet
English: EU/1/09/569/005 90 film-coated tablets
Slovenian: EU/1/09/569/005 90 filmsko obloženih tablet
English: EU/1/09/569/054 98 film-coated tablets
Slovenian: EU/1/09/569/054 98 filmsko obloženih tablet
English: EU/1/09/569/040 56 film-coated tablets
Slovenian: EU/1/09/569/040 56 filmsko obloženih tablet
English: EU/1/09/569/019 280 film-coated tablets
Slovenian: EU/1/09/569/019 280 filmsko obloženih tablet
English: EU/1/09/569/052 56 film-coated tablets
Slovenian: EU/1/09/569/052 56 filmsko obloženih tablet
English: Exforge HCT 5 mg/160 mg/25 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “VEL” on the other side.
Slovenian: Exforge HCT 5 mg/160 mg/25 mg filmsko obložene tablete so rumene ovalne tablete z oznako “NVR” na eni strani in “VEL” na drugi.
English: EU/1/09/569/003 30 film-coated tablets
Slovenian: EU/1/09/569/003 30 filmsko obloženih tablet
English: Exforge HCT 10 mg/320 mg/25 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Slovenian: Exforge HCT 10 mg/320 mg/25 mg filmsko obložene tablete Učinkovine v zdravilu Exforge HCT so amlodipin (v obliki amlodipinijevega besilata), valsartan in hidroklorotiazid.
English: EU/1/09/569/025 14 film-coated tablets
Slovenian: EU/1/09/569/025 14 filmsko obloženih tablet
English: Exforge HCT 10 mg/320 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Slovenian: Exforge HCT 10 mg/320 mg/25 mg filmsko obložene tablete amlodipin/valsartan/hidroklorotiazid
English: EU/1/09/569/026 28 film-coated tablets
Slovenian: EU/1/09/569/026 28 filmsko obloženih tablet
English: EU/1/09/569/053 90 film-coated tablets
Slovenian: EU/1/09/569/053 90 filmsko obloženih tablet
English: EU/1/09/569/029 90 film-coated tablets
Slovenian: EU/1/09/569/029 90 filmsko obloženih tablet
English: EU/1/09/569/049 14 film-coated tablets
Slovenian: EU/1/09/569/049 14 filmsko obloženih tablet
English: Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets are pale yellow, oval tablets with “NVR” on one side and “VDL” on the other side.
Slovenian: Exforge HCT 10 mg/160 mg/12,5 mg filmsko obložene tablete so bledo rumene ovalne tablete z oznako “NVR” na eni strani in “VDL” na drugi.
English: EU/1/09/569/017 90 film-coated tablets
Slovenian: EU/1/09/569/017 90 filmsko obloženih tablet
English: EU/1/09/569/051 30 film-coated tablets
Slovenian: EU/1/09/569/051 30 filmsko obloženih tablet
English: EU/1/09/569/037 14 film-coated tablets
Slovenian: EU/1/09/569/037 14 filmsko obloženih tablet
English: EU/1/09/569/014 28 film-coated tablets
Slovenian: EU/1/09/569/014 28 filmsko obloženih tablet
English: EU/1/09/569/002 28 film-coated tablets
Slovenian: EU/1/09/569/002 28 filmsko obloženih tablet
English: Talk to your doctor or pharmacist before taking Exforge HCT if you have a low level of potassium or magnesium in your blood (with or without symptoms such as muscle weakness, muscle spasms, abnormal heart rhythm).
Slovenian: Pred začetkom jemanja zdravila Exforge HCT se posvetujte z zdravnikom ali farmacevtom če imate v krvi nizke ravni kalija ali magnezija (s simptomi, kot so šibkost mišic, mišični krči in nepravilen srčni ritem, ali brez teh simptomov); če imate v krvi nizke ravni natrija (s simptomi, kot so utrujenost, zmedenost, trzanje mišic in napadi krčev, ali brez teh simptomov); če imate v krvi visoko raven kalcija (s simptomi, kot so slabost, bruhanje, zapeka, bolečine v trebuhu, pogosto uriniranje, žeja, šibkost in trzanje mišic, ali brez teh simptomov); če imate težave z ledvicami, če so vam presadili ledvico ali so vam povedali, da imate zoženje ledvičnih arterij; če imate težave z jetri; če imate ali ste imeli kdaj prej srčno popuščanje ali koronarno bolezen, zlasti če vam je zdravnik predpisal najvišji odmerek zdravila Exforge HCT (10 mg/320 mg/25 mg); če ste preživeli srčni infarkt.
English: EU/1/09/569/015 30 film-coated tablets
Slovenian: EU/1/09/569/015 30 filmsko obloženih tablet
English: EU/1/09/569/013 14 film-coated tablets
Slovenian: EU/1/09/569/013 14 filmsko obloženih tablet
English: Exforge HCT 10 mg/160 mg/25 mg film-coated tablets are brown-yellow, oval tablets with “NVR” on one side and “VHL” on the other side.
Slovenian: Exforge HCT 10 mg/160 mg/25 mg filmsko obložene tablete so rjavo rumene ovalne tablete z oznako “NVR” na eni strani in “VHL” na drugi.
English: EU/1/09/569/039 30 film-coated tablets
Slovenian: EU/1/09/569/039 30 filmsko obloženih tablet
English: Exforge HCT should be discontinued if hypercalcaemia develops during treatment.
Slovenian: Če pride med zdravljenjem do razvoja hiperkalciemije, je treba uporabo zdravila Exforge HCT prekiniti.
English: EU/1/09/569/050 28 film-coated tablets
Slovenian: EU/1/09/569/050 28 filmsko obloženih tablet
English: EU/1/09/569/032 56 x 1 film-coated tablet (unit dose) EU/1/09/569/033 98 x 1 film-coated tablet (unit dose) EU/1/09/569/034 280 x 1 film-coated tablet (unit dose)
Slovenian: EU/1/09/569/032 56 x 1 filmsko obložena tableta (za enkratni odmerek) EU/1/09/569/033 98 x 1 filmsko obložena tableta (za enkratni odmerek) EU/1/09/569/034 280 x 1 filmsko obložena tableta (za enkratni odmerek)
English: EU/1/09/569/044 56 x 1 film-coated tablet (unit dose) EU/1/09/569/045 98 x 1 film-coated tablet (unit dose) EU/1/09/569/046 280 x 1 film-coated tablet (unit dose)
Slovenian: EU/1/09/569/044 56 x 1 filmsko obložena tableta (za enkratni odmerek) EU/1/09/569/045 98 x 1 filmsko obložena tableta (za enkratni odmerek) EU/1/09/569/046 280 x 1 filmsko obložena tableta (za enkratni odmerek)
English: Exforge HCT 5 mg/160 mg/25 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Slovenian: Exforge HCT 5 mg/160 mg/25 mg filmsko obložene tablete Učinkovine v zdravilu Exforge HCT so amlodipin (v obliki amlodipinijevega besilata), valsartan in hidroklorotiazid.
English: EU/1/09/569/056 56 x 1 film-coated tablet (unit dose) EU/1/09/569/057 98 x 1 film-coated tablet (unit dose) EU/1/09/569/058 280 x 1 film-coated tablet (unit dose)
Slovenian: EU/1/09/569/056 56 x 1 filmsko obložena tableta (za enkratni odmerek) EU/1/09/569/057 98 x 1 filmsko obložena tableta (za enkratni odmerek) EU/1/09/569/058 280 x 1 filmsko obložena tableta (za enkratni odmerek)
English: Exforge HCT 5 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Slovenian: Exforge HCT 5 mg/160 mg/25 mg filmsko obložene tablete amlodipin/valsartan/hidroklorotiazid
English: EU/1/09/569/028 56 film-coated tablets
Slovenian: EU/1/09/569/028 56 filmsko obloženih tablet
English: EU/1/09/569/008 56 x 1 film-coated tablet (unit dose) EU/1/09/569/009 98 x 1 film-coated tablet (unit dose) EU/1/09/569/010 280 x 1 film-coated tablet (unit dose)
Slovenian: EU/1/09/569/008 56 x 1 filmsko obložena tableta (za enkratni odmerek) EU/1/09/569/009 98 x 1 filmsko obložena tableta (za enkratni odmerek) EU/1/09/569/010 280 x 1 filmsko obložena tableta (za enkratni odmerek)
English: Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Slovenian: Exforge HCT 5 mg/160 mg/12,5 mg filmsko obložene tablete Učinkovine v zdravilu Exforge HCT so amlodipin (v obliki amlodipinijevega besilata), valsartan in hidroklorotiazid.
English: Exforge HCT 10 mg/160 mg/25 mg film-coated tablets amlodipine/valsartan/hydrochlorothiaziade
Slovenian: Exforge HCT 10 mg/160 mg/25 mg filmsko obložene tablete amlodipin/valsartan/hidroklorotiazid
English: Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Slovenian: Exforge HCT 10 mg/160 mg/12,5 mg filmsko obložene tablete Učinkovine v zdravilu Exforge HCT so amlodipin (v obliki amlodipinijevega besilata), valsartan in hidroklorotiazid.
English: Exforge HCT 10 mg/160 mg/25 mg film-coated tablets The active substances of Exforge HCT are amlodipine (as amlodipine besylate), valsartan and hydrochlorothiazide.
Slovenian: Exforge HCT 10 mg/160 mg/25 mg filmsko obložene tablete Učinkovine v zdravilu Exforge HCT so amlodipin (v obliki amlodipinijevega besilata), valsartan in hidroklorotiazid.